Navigation Links
Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
Date:9/22/2008

Phase III Study to Explore the Effects of Oral Calcitonin, a combination of Salmon Calcitonin and Eligen Delivery Technology on Knee Osteoarthritis Treatment

CEDAR KNOLLS, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG and Nordic Bioscience have completed recruitment for a multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen Technology to treat patients with osteoarthritis of the knee. This study, which will be used to support the filing with health authorities worldwide, includes more than 1,100 patients between 51 and 80 years old with a medical history and symptoms of knee osteoarthritis. The study will be conducted mainly in Europe and is estimated to complete second half 2010.

Osteoarthritis ("OA") is a clinical syndrome in which low-grade inflammation results in joint pain, caused by a wearing-away of cartilage that cushions the joints and the destruction or decrease of synovial fluid that lubricates those joints. As OA progresses, pain can result when the patient bears weight upon the joints, including walking and standing. OA is the most common form of arthritis, and affects nearly 21 million people in the United States, accounting for 25% of visits to primary care physicians, and half of all non-steroidal anti-inflammatory drug prescriptions. It is estimated that 80% of the population will have radiographic evidence of OA by age 65.

"The problems associated with osteoarthritis will escalate as the population ages," said Michael V. Novinski, President and Chief Executive Officer of Emisphere. "This Phase III study aims at demonstrating that ora
'/>"/>

SOURCE Emisphere Technologies, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
3. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
4. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
5. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
6. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
7. Emisphere to Host Business Strategy Conference Call on February 7
8. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
9. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
10. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... , today announced that it will release its unaudited ... 2015, after market close on Wednesday, August 12, 2015. The ... 13, 2015, at 8:00 a.m. EDT (Thursday, August 13, ... the Company,s financial results and provide an update on ...
(Date:8/3/2015)... MARIETTA, Ga. , Aug. 3, 2015  MiMedx ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... will present at the 35 th Annual Canaccord|Genuity ...  Parker H. "Pete" Petit, Chairman and CEO, William ...
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a ... autologous cell therapies, announced today that RepliCel,s CEO, David ... in Minneapolis, Minnesota on August 5 ... highlight RepliCel,s 18-month milestones including CE Mark for its RCI-02 ... clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2
... 2010 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... breakthrough treatments for human disease, today updated the progress ... for the three and nine months ended September 30, ... new mechanisms of action in irritable bowel syndrome and ...
... 5, 2010 Tomophase Corporation, a leading developer of ... announced that it has received an award from the ... for the Qualifying Therapeutic Discovery Project (QTDP.) ... sponsored program that is targeted to projects that show ...
... today released the first in a series of video ... technology correspondent Miles O,Brien and currently airing nationally on ... quick look at what happens when genius meets possibility: ... shaping our world. The 26-part video series is ...
Cached Biology Technology:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 2Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 3Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 4Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 5Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 6Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 7Tomophase Receives Qualifying Therapeutic Discovery Project (QTDP) Award 2
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:8/3/2015)... Calif. , Aug. 3, 2015 Synaptics, ... human interface solutions, today announced that members of the ... at the Pacific Crest Global Technology Leadership Forum on ... The conference will be held at the Sonnenalp Resort ... The presentation may include forward-looking information. An audio ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... Whether or not a fertilized mammalian egg ultimately develops into ... a tug of war between two different genes encoding signaling ... new study led by Duke University Medical Center cell biologists. ... two specific genes, Wnt4 and Fgf9, are in equal balance ...
... entire superfamily of nuclear receptors ?proteins that turn genes ... Center researchers found that certain receptors form networks and ... main areas, reproduction and nutrient metabolism. , Receptor networks ... found. , The findings, published today in two studies ...
... human subjects to operate a robot-controlled joystick, Johns Hopkins researchers ... certain muscle movements, the more likely it is to remember ... say, could alter rehabilitation approaches for people who have lost ... a report on the work in the May 23 issue ...
Cached Biology News:Genetic tug of war determines sexual differentiation 2Genetic tug of war determines sexual differentiation 3First 'encyclopedia' of nuclear receptors reveals organisms' focus on sex, food 2First 'encyclopedia' of nuclear receptors reveals organisms' focus on sex, food 3New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: